CION Ameerpet
A hemangioblastoma is a benign, slow-growing tumour made of tiny blood vessels, most often in the cerebellum. It can be a one-off or part of Von Hippel-Lindau (VHL) disease. CION explains your MRI, the VHL question, and your options — calmly and clearly.
A hemangioblastoma is a benign (non-cancerous), slow-growing tumour made up of many tiny blood vessels — which is why doctors call it "highly vascular". It is classed as a WHO Grade 1 tumour. It is not a brain cancer, and it does not spread to other parts of the body.
Most hemangioblastomas develop in the cerebellum — the part at the back of the brain that controls balance and coordination — and some appear in the brainstem or spinal cord. Many are found alongside a fluid-filled cyst. The key question your team will ask is whether the tumour is a one-off (sporadic) or part of an inherited condition called Von Hippel-Lindau (VHL) disease — which changes the follow-up plan. This page explains the symptoms, how an MRI confirms the tumour, the VHL link, and the treatment paths, written and reviewed by the CION neuro-oncology team. You can also read our wider brain tumour overview for context on benign and malignant tumours.
Hemangioblastomas are the most common primary tumour of the cerebellum in adults, yet they are still uncommon overall. Around a quarter to a third of cases are linked to Von Hippel-Lindau (VHL) disease, an inherited condition. The EANO and NCCN emphasise that finding more than one hemangioblastoma, or a case at a young age, should prompt assessment for VHL — because it changes surveillance and family screening.
Symptoms depend on where the tumour is and whether a surrounding cyst is pressing on nearby structures. They usually build up gradually over weeks to months. Because the cerebellum is the most common site, the classic signs relate to balance and raised pressure:
A single symptom on its own is rarely due to a tumour — dizziness, headaches, and clumsiness usually have everyday causes. What deserves prompt assessment is a symptom that is new, persistent, and progressive, or a headache that wakes you from sleep or comes with vomiting. If this sounds like you, talk to a CION specialist about an MRI.
This is the single most important question after a hemangioblastoma is found. Hemangioblastomas fall into two groups, and the difference shapes your whole follow-up plan:
Most hemangioblastomas are sporadic — a single tumour, with no inherited cause and no family link. A sporadic hemangioblastoma that is completely removed is usually cured, and long-term surveillance of the rest of the nervous system is not usually needed in the same way.
In VHL disease, an inherited change in the VHL gene leads to multiple hemangioblastomas over a lifetime — in the brain, spinal cord, and retina — plus a higher risk of kidney tumours and other growths. VHL is why lifelong MRI surveillance and family screening matter.
Clues that VHL may be involved include more than one hemangioblastoma, tumours at a young age, a hemangioblastoma in the retina of the eye, or a family history. When these are present, we arrange genetic assessment and coordinate the wider surveillance VHL requires. For a full explanation, read our dedicated page on Von Hippel-Lindau disease and hemangioblastoma.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Whether you've just seen "hemangioblastoma" on a scan report or you're weighing monitoring against treatment, our team will talk you through it — including whether VHL testing is right for you — calmly and without pressure.
Diagnosis centres on imaging, because these tumours have a fairly recognisable appearance and are too vascular for a routine needle biopsy.
The main test is an MRI with gadolinium contrast. Hemangioblastomas typically show up as a small, brightly enhancing nodule, often sitting next to a larger fluid-filled cyst — most commonly in the cerebellum. MRI measures the tumour's exact size and position, shows any cyst, and reveals its relationship to the brainstem. Because VHL can cause tumours in the spinal cord too, the spine is often scanned as well. Learn more about brain tumour diagnosis and treatment at CION.
Unlike many brain tumours, a hemangioblastoma is rarely biopsied with a needle — because it is packed with blood vessels, a needle carries a real bleeding risk. Instead, for tumours that need treatment, surgery serves as both the diagnosis and the treatment: the removed tumour is examined to confirm the type. For small, symptom-free tumours, the typical MRI appearance and monitoring often make a confident working diagnosis without any procedure.
If more than one hemangioblastoma is found, or you are young or have a family history, we arrange assessment for VHL disease — usually a genetic blood test plus screening for tumours elsewhere (eyes, kidneys, adrenal glands). Confirming or ruling out VHL determines whether you need lifelong surveillance and whether family members should be offered testing.
There is rarely a single "right" answer. The best choice depends on the tumour's size, location, whether it is growing or causing symptoms, and whether VHL is involved. NCCN and EANO recognise all three approaches below.
For small tumours that cause no symptoms — often found incidentally, especially in people with VHL — the safest plan is frequently to monitor with repeat MRI rather than treat straight away. Because these tumours can stay stable for years, this avoids the risks of treatment unless and until the tumour actually grows or a cyst enlarges.
For accessible, symptomatic, or growing tumours, complete surgical removal is the mainstay and often curative for a single sporadic tumour. Because hemangioblastomas are highly vascular, surgery is carefully planned. At CION this is coordinated with our accredited neurosurgical partners, who perform the operation — while our team manages your imaging, any radiation, and the wider plan.
For tumours that are small, deep, surgically difficult, or multiple (as in VHL), stereotactic radiosurgery delivers highly focused radiation from many angles at once — with no incision. Despite the name, no cutting is involved. CION plans and delivers radiation directly as part of coordinated radiosurgery and specialist care.
Hemangioblastoma care touches several specialties, so it helps to know exactly who does what at CION:
This means you are not bounced between disconnected providers. One coordinated team holds your imaging, your decisions, and your follow-up together — which matters most when VHL requires care across the brain, spine, and other organs.
Much of the trouble a cerebellar hemangioblastoma causes comes not from the tumour itself but from the fluid-filled cyst that often surrounds it. As the cyst enlarges, it raises pressure and triggers headaches and unsteadiness. This is why MRI monitoring watches both the tumour nodule and any cyst — and why symptoms can appear even when the solid tumour is small.
A hemangioblastoma is benign and usually slow-growing, which means you often have time to make a calm, well-informed decision. A second opinion is especially worthwhile if:
At CION, your case goes to a multidisciplinary tumour board, and we offer a free written second opinion after a 45-minute consultation. We walk this journey with you. Book your free consultation or call 18002028726. You may also want to read about the Von Hippel-Lindau link before you decide.
Get a free written second opinion from CION's tumour board — particularly valuable before agreeing to surgery, or if the Von Hippel-Lindau question and full spine imaging haven't been discussed with you.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.No. A hemangioblastoma is a benign (non-cancerous), slow-growing tumour made of many tiny blood vessels. It is classed as a WHO Grade 1 tumour and does not spread to other parts of the body the way cancer does. Most develop in the cerebellum (the balance centre at the back of the brain), and some in the brainstem or spinal cord. Because it sits in a tight, delicate space, a growing tumour — or a fluid-filled cyst around it — can press on nearby structures and cause symptoms. So even though it is benign, it is watched carefully and treated when it grows or causes problems.
Hemangioblastomas can be sporadic (a one-off, with no inherited cause) or part of Von Hippel-Lindau (VHL) disease, a rare inherited condition. In VHL, people tend to develop multiple hemangioblastomas over time — often in the brain, spinal cord, and retina (the eye) — along with a higher risk of kidney tumours and other growths. A key clue that VHL may be involved is more than one hemangioblastoma, tumours at a young age, or a family history. If VHL is suspected, genetic testing and lifelong surveillance are important. Read more about Von Hippel-Lindau disease and hemangioblastoma.
Symptoms depend on where the tumour is. In the cerebellum — the most common site — they often reflect raised pressure and balance problems: headache (sometimes worse in the morning), nausea or vomiting, unsteadiness, clumsiness, or trouble with coordination, and dizziness. A tumour in the brainstem can affect swallowing, speech, or eye movements, and one in the spinal cord can cause weakness, numbness, or pain. Symptoms usually build gradually. Any new, persistent, and progressive neurological symptom deserves assessment with an MRI scan.
Not always. Small, symptom-free hemangioblastomas — often found incidentally, especially in people with VHL — may simply be monitored with repeat MRI. Treatment is considered when the tumour grows, when a surrounding cyst enlarges, or when symptoms develop. The main option for accessible tumours is surgical removal, which is coordinated with our accredited neurosurgical partners. For small, deep, or multiple tumours, stereotactic radiosurgery (focused radiation, no incision) may be used. The right choice depends on tumour size, location, symptoms, and whether VHL is involved — decided by our tumour board.
CION delivers the oncology-led parts of hemangioblastoma care directly — MRI diagnosis and characterisation, monitoring, stereotactic radiosurgery planning and delivery, steroid and symptom management, and supportive care. When surgical removal is the right choice, it is coordinated with our accredited neurosurgical partners, who perform the operation, while our team manages the imaging, any radiation, and the overall plan. Because these tumours are highly vascular (full of blood vessels), planning is careful and multidisciplinary. You get one coordinated pathway rather than being sent between disconnected providers.
A single sporadic hemangioblastoma that is completely removed by surgery is usually cured, and recurrence at that spot is uncommon. However, in people with Von Hippel-Lindau disease, new hemangioblastomas can appear over time in different locations — which is why lifelong MRI surveillance of the brain and spine is recommended for anyone with VHL. This is not the same as the original tumour "coming back"; it is a new growth. Regular monitoring means new tumours are found early, when there are usually more options and simpler treatment.
The main test is an MRI of the brain (and often the spine) with contrast. Hemangioblastomas have a fairly typical appearance — a small, brightly enhancing nodule often sitting alongside a fluid-filled cyst, most commonly in the cerebellum. Because the tumour is so vascular, surgery serves as both diagnosis and treatment for accessible tumours; a separate needle biopsy is usually avoided due to bleeding risk. If more than one tumour is seen, or you are young or have a family history, testing for Von Hippel-Lindau disease is arranged. At CION, imaging is read by specialists who plan the safest next step.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.